Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Acorda Therapeutics (ACOR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 652,096
  • Shares Outstanding, K 47,633
  • Annual Sales, $ 471,430 K
  • Annual Income, $ 33,680 K
  • 60-Month Beta 1.49
  • Price/Sales 1.45
  • Price/Cash Flow 6.09
  • Price/Book 1.12

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.82
  • Number of Estimates 2
  • High Estimate -0.67
  • Low Estimate -0.97
  • Prior Year -0.18
  • Growth Rate Est. (year over year) -355.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.55 +9.88%
on 02/22/19
15.41 -10.51%
on 03/01/19
+0.41 (+3.06%)
since 02/21/19
3-Month
12.55 +9.88%
on 02/22/19
17.57 -21.51%
on 01/11/19
+0.85 (+6.57%)
since 12/21/18
52-Week
12.55 +9.88%
on 02/22/19
36.35 -62.06%
on 06/08/18
-10.36 (-42.90%)
since 03/21/18

Most Recent Stories

More News
Acorda to Present New Long-Term Data for INBRIJA(TM) (levodopa inhalation powder) at Academy of Managed Care Pharmacy Annual Meeting

Acorda Therapeutics, Inc. (NASDAQ: ACOR) will present three posters with Phase 3 data on INBRIJA at the upcoming Academy of Managed Care Pharmacy (AMCP) Managed Care & Specialty Pharmacy...

ACOR : 13.83 (+1.02%)
Acorda (ACOR) Down 6% Since Last Earnings Report: Can It Rebound?

Acorda (ACOR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ACOR : 13.83 (+1.02%)
Acorda Therapeutics (ACOR) Gains But Lags Market: What You Should Know

In the latest trading session, Acorda Therapeutics (ACOR) closed at $14.62, marking a +0.14% move from the previous day.

ACOR : 13.83 (+1.02%)
Acorda Therapeutics Announces Management Changes

Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that Andrew Hindman, Chief Business Officer, will transition out of the Company over the coming months.

ACOR : 13.83 (+1.02%)
Acorda to Present at Oppenheimer's 29th Annual Healthcare Conference

Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Andrew Hindman, Acorda's Chief Business Officer, will present at the Oppenheimer & Co. Annual Healthcare Conference on Tuesday, March...

ACOR : 13.83 (+1.02%)
Glancy Prongay & Murray LLP Announces Investigation on Behalf of Acorda Therapeutics, Inc. Investors (ACOR)

EQNX::TICKER_START (NASDAQ:ACOR), EQNX::TICKER_END

ACOR : 13.83 (+1.02%)
Detailed Research: Economic Perspectives on Huntsman, eHealth, Ionis Pharmaceuticals, Arch Capital Group, Copart, and Acorda Therapeutics -- What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Huntsman Corporation (NYSE:HUN),...

HUN : 23.02 (+3.09%)
CPRT : 60.04 (+1.50%)
EHTH : 62.73 (+10.25%)
IONS : 80.15 (-0.07%)
ACGL : 32.41 (+1.34%)
ACOR : 13.83 (+1.02%)
Acorda Therapeutics Announces Commercial Launch of INBRIJA(TM) (levodopa inhalation powder)

Acorda Therapeutics, Inc. (NASDAQ: ACOR) today announced that INBRIJA is now available by prescription in the United States. INBRIJA was approved by the U.S. Food and Drug Administration...

ACOR : 13.83 (+1.02%)
SmarTrend Watching for Potential Pullback in Shares of Acorda Therapeut After 1.94% Gain

Acorda Therapeut (NASDAQ:ACOR) traded in a range yesterday that spanned from a low of $13.61 to a high of $13.68. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high...

ACOR : 13.83 (+1.02%)
Acorda Therapeutics to Present at Cowen Annual Health Care Conference

Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., Acorda's President and Chief Executive Officer, will present at the Cowen and Company Global Health Care Conference...

ACOR : 13.83 (+1.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade ACOR with:

Business Summary

Acorda Therapeutics, Inc. is a biotechnology company developing and commercializing neurology therapies for Parkinson's disease, migraine and multiple sclerosis. Acorda has a pipeline of novel neurological therapies addressing a range of disorders, including Parkinson's disease and multiple sclerosis....

See More

Key Turning Points

2nd Resistance Point 14.77
1st Resistance Point 14.23
Last Price 13.83
1st Support Level 13.33
2nd Support Level 12.97

See More

52-Week High 36.35
Fibonacci 61.8% 27.26
Fibonacci 50% 24.45
Fibonacci 38.2% 21.64
Last Price 13.83
52-Week Low 12.55

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar